-
Mashup Score: 22In adults with ATTR cardiac amyloidosis, patisiran reduced decline in functional capacity at 12 mo | Annals of Internal Medicine - 1 month(s) ago
Source Citation Maurer MS, Kale P, Fontana M, et al; APOLLO-B Trial Investigators. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med. 2023;389:1553-1565. 37888916
Source: www.acpjournals.orgCategories: General Medicine News, CardiologistsTweet
Appraisal of #ApolloB #RCT for #ACPJournalClub w @MasriAhmadMD @AnnalsofIM In RCT of 360 ppl w #ATTR cardiac #amyloidosis, those on #patisiran experienced modest improvem’t in #6MWT Unclear benefit in those on tafamidis 🔗 https://t.co/9MEPU6AYsx 🔗 https://t.co/a45tThktTd https://t.co/wmfB1okPxv